ZANTAC 150
LOE ApproachingNDAORALTABLET
Approved
Jun 1983
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 15h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZANTAC 150 is an oral tablet small-molecule H2-receptor antagonist approved in 1983 for acid-related gastrointestinal disorders. The drug reduces gastric acid secretion and is indicated for conditions such as peptic ulcer disease and gastroesophageal reflux disease (GERD). It represents a mature, well-established therapy in the H2-blocker class.
LOE Approaching
As LOE approaches, the brand team is likely focused on lifecycle management, cost control, and potential transition planning rather than aggressive growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Bioavailability Study of Ranitidine Hydrochloride (Maximum Strength ZANTAC 150®) Compared to Two Different 150 mg Ranitidine Hydrochloride Oral Disintegrating Tablet (ODT) in Fasting, Healthy Male Volunteers
Started May 2009
42 enrolled
Healthy
Career Relevance
Working on ZANTAC 150 offers limited growth trajectory but provides deep experience in mature product lifecycle management, generic competition strategies, and cost optimization. This role suits professionals seeking stable positions focused on operational excellence rather than innovation-driven expansion.
Brand Manager
Worked on ZANTAC 150 at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.